1.81
+7.74%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Century Therapeutics
From its filings with the US Securities and Exchange Commission
Century Therapeutics is based in Philadelphia, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IPSC. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $109.2m and a net loss of $9.6m. At that date it held total assets of $223.7m and shareholders' equity of $158.9m.
We are leveraging our expertise in cellular reprogramming, differentiation, genetic engineering, and manufacturing to develop therapies with the potential to provide enhanced clinical outcomes compared to existing cell therapy technologies and available therapeutic options. We are unique in the breadth of cell types we can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ ab T cells, or ab iT cells, and iPSC- natural killer cells, or iNK cells. We believe this capability enables optimal matching of cell characteristics to disease indication, ensuring we target the right cell for the right indication.
Our vision is to become a premier, fully integrated biotechnology company by developing and ultimately commercializing off-the-shelf allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from T1D, autoimmune diseases and cancers. To achieve our vision, our world-class team is applying its decades of collective experience in cell therapy and drug development, manufacturing, and commercialization.
In November 2025, we announced our plans to develop a beta islet program, CNTY-813, for T1D. We are leveraging our deep expertise in selective iPSC differentiation to advance this program, engineered with Allo-Evasion™ 5.0, toward clinical evaluation subject to regulatory clearance. We have moved CNTY-813 into IND-enabling studies and anticipate submission of an IND application as early as 2026.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jun 2021
- Employees
- 78
- Website
- centurytx.com ↗
- Head office
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Brent PfeiffenbergerChairman of the Board, President, Chief Executive Officer, since 2023$2.2m
- Mr. Douglas CarrInterim Chief Financial Officer
- Dr. Gregory RussottiChief Technology and Manufacturing Officer$1.5m
- Dr. Chad CowanChief Scientific Officer
- Dr. Kimberly BlackwellIndependent Director$132,592
- Dr. Han LeeIndependent Director
- Dr. Martin MurphyIndependent Director
- Ms. Daphne QuimiIndependent Director$140,092
- Dr. Alessandro RivaIndependent Director$128,592
- Mr. Timothy WalbertIndependent Director$126,092
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 65
- Social
- 76
- Governance
- 45
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on developing transformative allogeneic cell therapies for cancer treatment.
- Has a platform including induced pluripotent stem cells (iPSCs) and differentiation know-how.
- Product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106.
Weaknesses
- The company has a small employee count of 78 as per the provided data.
- The source description states 163 employees, which contradicts the provided 78.
- The company is focused on a niche area of biotechnology with high development risks.
Opportunities
- The firm's platform can be used for developing treatments for solid tumors and hematological malignancies.
- There is potential for collaboration programs like CNTY-104 for acute myeloid leukemia.
- The focus on unmet medical needs in cancer care presents market opportunities.
Threats
- The biotechnology sector faces high regulatory hurdles and development costs.
- The company's reliance on a single platform may limit diversification.
- Competition in the cell therapy market could impact market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.